TY - JOUR AU - Siegel, R. L. AU - Miller, K. D. AU - Jemal, A. PY - 2020 DA - 2020// TI - Cancer statistics, 2020 JO - CA Cancer J Clin VL - 70 UR - https://doi.org/10.3322/caac.21590 DO - 10.3322/caac.21590 ID - Siegel2020 ER - TY - JOUR AU - Conroy, T. AU - Desseigne, F. AU - Ychou, M. PY - 2011 DA - 2011// TI - FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer JO - N Engl J Med VL - 364 UR - https://doi.org/10.1056/NEJMoa1011923 DO - 10.1056/NEJMoa1011923 ID - Conroy2011 ER - TY - JOUR AU - Hoff, D. D. AU - Ervin, T. AU - Arena, F. P. PY - 2013 DA - 2013// TI - Increased survival in pancreatic Cancer with nab-paclitaxel plus gemcitabine JO - N Engl J Med VL - 369 UR - https://doi.org/10.1056/NEJMoa1304369 DO - 10.1056/NEJMoa1304369 ID - Hoff2013 ER - TY - STD TI - Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with Osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa1913662. ID - ref4 ER - TY - JOUR AU - Chapman, P. B. AU - Hauschild, A. AU - Robert, C. PY - 2011 DA - 2011// TI - Improved survival with Vemurafenib in melanoma with BRAF V600E mutation JO - N Engl J Med VL - 364 UR - https://doi.org/10.1056/NEJMoa1103782 DO - 10.1056/NEJMoa1103782 ID - Chapman2011 ER - TY - STD TI - Saiki Y, Horii A. Molecular pathology of pancreatic cancer. Pathol Int. 2014. https://doi.org/10.1111/pin.12114. ID - ref6 ER - TY - STD TI - Welsch ME, Kaplan A, Chambers JM, et al. Multivalent Small-Molecule Pan-RAS Inhibitors. Cell. 2017;168(5):878–889.e29. doi:doi:https://doi.org/10.1016/j.cell.2017.02.006 ID - ref7 ER - TY - JOUR AU - Sheridan, C. PY - 2020 DA - 2020// TI - Grail of RAS cancer drugs within reach JO - Nat Biotechnol VL - 38 UR - https://doi.org/10.1038/s41587-019-0382-x DO - 10.1038/s41587-019-0382-x ID - Sheridan2020 ER - TY - JOUR AU - Waddell, N. AU - Pajic, M. AU - Patch, A. -. M. PY - 2015 DA - 2015// TI - Whole genomes redefine the mutational landscape of pancreatic cancer JO - Nature. VL - 518 UR - https://doi.org/10.1038/nature14169 DO - 10.1038/nature14169 ID - Waddell2015 ER - TY - STD TI - Yachida S, White CM, Naito Y, et al. Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors. Clin Cancer Res. 2012. https://doi.org/10.1158/1078-0432.CCR-12-1215. ID - ref10 ER - TY - JOUR AU - Harsha, H. C. AU - Pandey, A. PY - 2010 DA - 2010// TI - Phosphoproteomics in cancer JO - Mol Oncol VL - 4 UR - https://doi.org/10.1016/j.molonc.2010.09.004 DO - 10.1016/j.molonc.2010.09.004 ID - Harsha2010 ER - TY - STD TI - Cutillas PR. The role of phosphoproteomics in the development of personalized cancer therapies. Proteomics Clin Appl. 2014:1–18. https://doi.org/10.1002/prca.201400104.This. ID - ref12 ER - TY - STD TI - Fleuren EDG, Vlenterie M, Graaf WTA Van Der, et al. Phosphoproteomic Pro fi ling Reveals ALK and MET as Novel Actionable Targets across Synovial Sarcoma Subtypes 2017:4279–4293. doi:https://doi.org/10.1158/0008-5472.CAN-16-2550. ID - ref13 ER - TY - JOUR AU - Rikova, K. AU - Guo, A. AU - Zeng, Q. PY - 2007 DA - 2007// TI - Global survey of Phosphotyrosine signaling identifies oncogenic kinases in lung Cancer JO - Cell. VL - 131 UR - https://doi.org/10.1016/j.cell.2007.11.025 DO - 10.1016/j.cell.2007.11.025 ID - Rikova2007 ER - TY - JOUR AU - Furukawa, T. AU - Duguid, W. AU - Rosenberg, L. AU - Viallet, J. AU - Galloway, D. AU - Tsao, M. PY - 1996 DA - 1996// TI - Long-term culture and immortalization of epithelial cells from normal adult human pancreatic ducts transfected by the E6E7 gene of human papilloma virus 16 JO - Am J Pathol VL - 148 ID - Furukawa1996 ER - TY - JOUR AU - Avan, A. AU - Caretti, V. AU - Funel, N. PY - 2013 DA - 2013// TI - Crizotinib inhibits metabolic inactivation of gemcitabine in c-met-driven pancreatic carcinoma JO - Cancer Res VL - 73 UR - https://doi.org/10.1158/0008-5472.CAN-13-0837 DO - 10.1158/0008-5472.CAN-13-0837 ID - Avan2013 ER - TY - JOUR AU - Mijn, J. C. AU - Labots, M. AU - Piersma, S. R. PY - 2015 DA - 2015// TI - Evaluation of different phospho-tyrosine antibodies for label-free phosphoproteomics JO - J Proteome VL - 127 UR - https://doi.org/10.1016/j.jprot.2015.04.006 DO - 10.1016/j.jprot.2015.04.006 ID - Mijn2015 ER - TY - JOUR AU - Rush, J. AU - Moritz, A. AU - Lee, K. A. PY - 2005 DA - 2005// TI - Immunoaffinity profiling of tyrosine phosphorylation in cancer cells JO - Nat Biotechnol VL - 23 UR - https://doi.org/10.1038/nbt1046 DO - 10.1038/nbt1046 ID - Rush2005 ER - TY - JOUR AU - Piersma, S. R. AU - Warmoes, M. O. AU - Wit, M. AU - Reus, I. AU - Knol, J. C. AU - Jiménez, C. R. PY - 2013 DA - 2013// TI - Whole gel processing procedure for GeLC-MS/MS based proteomics JO - Proteome Sci VL - 11 UR - https://doi.org/10.1186/1477-5956-11-17 DO - 10.1186/1477-5956-11-17 ID - Piersma2013 ER - TY - JOUR AU - Cox, J. AU - Mann, M. PY - 2008 DA - 2008// TI - MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification JO - Nat Biotechnol VL - 26 UR - https://doi.org/10.1038/nbt.1511 DO - 10.1038/nbt.1511 ID - Cox2008 ER - TY - JOUR AU - Subramanian, A. AU - Tamayo, P. AU - Mootha, V. K. PY - 2005 DA - 2005// TI - Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles JO - Proc Natl Acad Sci U S A VL - 102 UR - https://doi.org/10.1073/pnas.0506580102 DO - 10.1073/pnas.0506580102 ID - Subramanian2005 ER - TY - JOUR AU - Raaijmakers, L. M. AU - Giansanti, P. AU - Possik, P. A. PY - 2015 DA - 2015// TI - PhosphoPath: visualization of Phosphosite-centric dynamics in temporal molecular networks JO - J Proteome Res VL - 14 UR - https://doi.org/10.1021/acs.jproteome.5b00529 DO - 10.1021/acs.jproteome.5b00529 ID - Raaijmakers2015 ER - TY - STD TI - Beekhof R, Alphen C, Henneman AA, et al. INKA , an integrative data analysis pipeline for phosphoproteomic inference of active kinases . Mol Syst Biol. 2019;15(4):1–22. doi:https://doi.org/10.15252/msb.20188250 ID - ref23 ER - TY - STD TI - Cavazzoni A, Monica S La, Alfieri R, et al. Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN 2017;8(32):53068–53083. ID - ref24 ER - TY - JOUR AU - Giovannetti, E. AU - Funel, N. AU - Peters, G. J. PY - 2010 DA - 2010// TI - MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity JO - Cancer Res VL - 70 UR - https://doi.org/10.1158/0008-5472.CAN-09-4467 DO - 10.1158/0008-5472.CAN-09-4467 ID - Giovannetti2010 ER - TY - JOUR AU - Large, T. Y. S. AU - Hassouni, B. AU - Funel, N. PY - 2019 DA - 2019// TI - Proteomic analysis of gemcitabine- resistant pancreatic cancer cells reveals that microtubule-associated protein 2 upregulation associates with taxane treatment JO - Ther Adv Med Oncol VL - 11 UR - https://doi.org/10.1177/https DO - 10.1177/https ID - Large2019 ER - TY - STD TI - Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science (80- ). 2002. doi:https://doi.org/10.1126/science.1075762 ID - ref27 ER - TY - JOUR AU - Sulzmaier, F. J. AU - Jean, C. AU - Schlaepfer, D. D. PY - 2014 DA - 2014// TI - FAK in cancer: mechanistic findings and clinical applications JO - Nat Rev Cancer VL - 14 UR - https://doi.org/10.1038/nrc3792 DO - 10.1038/nrc3792 ID - Sulzmaier2014 ER - TY - STD TI - Jones SF, G. Shapiro, J. C. Bendell, et al. Phase I study of PF-04554878, a second-generation focal adhesion kinase (FAK) inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2011;29: 2011:(suppl; abstr 3002). doi:https://doi.org/10.1007/s10637-015-0282-y ID - ref29 ER - TY - STD TI - Murphy JM, Rodriguez YAR, Jeong K, Ahn EE, Lim SS. Targeting focal adhesion kinase in cancer cells and the tumor microenvironment. Exp Mol Med. 2020;52(6):877-6. https://doi.org/10.1038/s12276-020-0447-4 ID - ref30 ER - TY - JOUR AU - Shimizu, T. AU - Fukuoka, K. AU - Takeda, M. PY - 2016 DA - 2016// TI - A first-in-asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of vs-6063, a focal adhesion kinase (FAK) inhibitor in japanese patients with advanced solid tumors JO - Cancer Chemother Pharmacol VL - 77 UR - https://doi.org/10.1007/s00280-016-3010-1 DO - 10.1007/s00280-016-3010-1 ID - Shimizu2016 ER - TY - STD TI - Klaeger S, Heinzlmeir S, Wilhelm M, et al. The target landscape of clinical kinase drugs. Science (80- ). 2017;358(6367):eaan4368. doi:https://doi.org/10.1126/science.aan4368 ID - ref32 ER - TY - JOUR AU - Lv, P. -. C. AU - Jiang, A. -. Q. AU - Zhang, W. -. M. AU - Zhu, H. -. L. PY - 2017 DA - 2017// TI - FAK inhibitors in Cancer, a patent review JO - Expert Opin Ther Pat VL - 28 UR - https://doi.org/10.1080/13543776.2018.1414183 DO - 10.1080/13543776.2018.1414183 ID - Lv2017 ER - TY - JOUR AU - Wang, Y. AU - McNiven, M. A. PY - 2012 DA - 2012// TI - Invasive matrix degradation at focal adhesions occurs via protease recruitment by a FAK-p130Cas complex JO - J Cell Biol VL - 196 UR - https://doi.org/10.1083/jcb.201105153 DO - 10.1083/jcb.201105153 ID - Wang2012 ER - TY - JOUR AU - Lee, B. Y. AU - Timpson, P. AU - Horvath, L. G. AU - Daly, R. J. PY - 2015 DA - 2015// TI - FAK signaling in human cancer as a target for therapeutics JO - Pharmacol Ther VL - 146 UR - https://doi.org/10.1016/j.pharmthera.2014.10.001 DO - 10.1016/j.pharmthera.2014.10.001 ID - Lee2015 ER - TY - STD TI - Sohal DPS, Kennedy EB, Khorana A, et al. Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2018:JCO.2018.78.9636. doi:https://doi.org/10.1200/JCO.2018.78.9636 ID - ref36 ER - TY - JOUR AU - Goldstein, D. AU - El-Maraghi, R. H. AU - Hammel, P. PY - 2015 DA - 2015// TI - Nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial JO - J Natl Cancer Inst VL - 107 UR - https://doi.org/10.1093/jnci/dju413 DO - 10.1093/jnci/dju413 ID - Goldstein2015 ER - TY - JOUR AU - Weaver, B. A. PY - 2014 DA - 2014// TI - How Taxol/paclitaxel kills cancer cells JO - Mol Biol Cell VL - 25 UR - https://doi.org/10.1091/mbc.E14-04-0916 DO - 10.1091/mbc.E14-04-0916 ID - Weaver2014 ER - TY - STD TI - Hashimoto D, Arima K, Yokoyama N, Chikamoto A. Heterogeneity of KRAS Mutations in Pancreatic Ductal Adenocarcinoma 2016;00(00):1–4. doi:https://doi.org/10.1097/MPA.0000000000000624. ID - ref39 ER - TY - STD TI - van Alphen C, Cloos J, Beekhof R, et al. Phosphotyrosine-based phosphoproteomics for target identification and drug response prediction in AML cell lines. Mol Cell Proteomics. 2020:mcp.RA119.001504. doi:https://doi.org/10.1074/mcp.ra119.001504 ID - ref40 ER - TY - JOUR AU - Piersma, S. R. AU - Knol, J. C. AU - Reus, I. PY - 2015 DA - 2015// TI - Feasibility of label-free phosphoproteomics and application to base-line signaling of colorectal cancer cell lines JO - J Proteome VL - 127 UR - https://doi.org/10.1016/j.jprot.2015.03.019 DO - 10.1016/j.jprot.2015.03.019 ID - Piersma2015 ER - TY - JOUR AU - Kim, M. -. S. AU - Zhong, Y. AU - Yachida, S. PY - 2014 DA - 2014// TI - Heterogeneity of pancreatic Cancer metastases in a single patient revealed by quantitative proteomics JO - Mol Cell Proteomics VL - 13 UR - https://doi.org/10.1074/mcp.M114.038547 DO - 10.1074/mcp.M114.038547 ID - Kim2014 ER - TY - STD TI - Humphrey ES, Shih-Ping S, Nagrial AM, et al. Resolution of novel pancreatic ductal adenocarcinoma subtypes by global phosphotyrosine profiling. Mol Cell Proteomics. 2016;(15(8)):2671–2685. doi:https://doi.org/10.1074/mcp.M116.058313 ID - ref43 ER - TY - JOUR AU - Le, N. AU - Vinci, A. AU - Schober, M. PY - 2017 DA - 2017// TI - Real-world clinical practice of intensified chemotherapies for metastatic pancreatic Cancer: results from a pan-European questionnaire study JO - Digestion. VL - 94 UR - https://doi.org/10.1159/000453257 DO - 10.1159/000453257 ID - Le2017 ER - TY - JOUR AU - Sinn, M. AU - Bahra, M. AU - Liersch, T. PY - 2017 DA - 2017// TI - CONKO-005: adjuvant chemotherapy with gemcitabine plus erlotinib versus gemcitabine alone in patients after r0 resection of pancreatic cancer: a multicenter randomized phase III trial JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2017.72.6463 DO - 10.1200/JCO.2017.72.6463 ID - Sinn2017 ER - TY - JOUR AU - Halfdanarson, T. R. AU - Foster, N. R. AU - Kim, G. P. PY - 2019 DA - 2019// TI - A phase II randomized trial of Panitumumab, Erlotinib, and gemcitabine versus Erlotinib and gemcitabine in patients with untreated, metastatic pancreatic adenocarcinoma: north central Cancer treatment group trial N064B (Alliance) JO - Oncologist. VL - 24 UR - https://doi.org/10.1634/theoncologist.2018-0878 DO - 10.1634/theoncologist.2018-0878 ID - Halfdanarson2019 ER - TY - STD TI - Koch H, Busto MEDC, Kramer K, Médard G, Kuster B. Chemical proteomics uncovers EPHA2 as a mechanism of acquired resistance to small molecule EGFR kinase inhibition. J Proteome Res. 2015. https://doi.org/10.1021/acs.jproteome.5b00161. ID - ref47 ER - TY - JOUR AU - Large, T. Y. AU - Mantini, G. AU - Meijer, L. L. PY - 2020 DA - 2020// TI - Microdissected pancreatic cancer proteomes reveal tumor heterogeneity and therapeutic targets JO - JCI Insight VL - 5 UR - https://doi.org/10.1172/jci.insight.138290 DO - 10.1172/jci.insight.138290 ID - Large2020 ER - TY - JOUR AU - Kanteti, R. AU - Mirzapoiazova, T. AU - Riehm, J. J. PY - 2018 DA - 2018// TI - Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma JO - Cancer Biol Ther VL - 19 UR - https://doi.org/10.1080/15384047.2017.1416937 DO - 10.1080/15384047.2017.1416937 ID - Kanteti2018 ER - TY - JOUR AU - Laklai, H. AU - Miroshnikova, Y. A. AU - Pickup, M. W. PY - 2016 DA - 2016// TI - Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression JO - Nat Med VL - 22 UR - https://doi.org/10.1038/nm.4082 DO - 10.1038/nm.4082 ID - Laklai2016 ER - TY - JOUR AU - Jiang, H. AU - Hegde, S. AU - Knolhoff, B. L. PY - 2016 DA - 2016// TI - Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy JO - Nat Med VL - 22 UR - https://doi.org/10.1038/nm.4123 DO - 10.1038/nm.4123 ID - Jiang2016 ER - TY - STD TI - Zaghdoudi S, Decaup E, Belhabib I, et al. FAK activity in cancer-associated fibroblasts is a prognostic marker and a druggable key metastatic player in pancreatic cancer. EMBO Mol Med. 2020. doi:https://doi.org/10.15252/emmm.202012010 ID - ref52 ER - TY - JOUR AU - Neesse, A. AU - Frese, K. K. AU - Chan, D. S. PY - 2014 DA - 2014// TI - SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice JO - Gut. VL - 63 UR - https://doi.org/10.1136/gutjnl-2013-305559 DO - 10.1136/gutjnl-2013-305559 ID - Neesse2014 ER - TY - STD TI - Manner F, Mcgrail DJ, Khambhati NN, Qi MX, Patel KS, Ravikumar N. Alterations in Ovarian Cancer Cell Adhesion Drive Taxol Resistance by Increasing Microtubule Dynamics in a 2015:e1–11. doi:https://doi.org/10.1038/srep09529. ID - ref54 ER - TY - JOUR AU - Tape, C. J. AU - Ling, S. AU - Dimitriadi, M. PY - 2016 DA - 2016// TI - Oncogenic KRAS regulates tumor cell signaling via stromal reciprocation JO - Cell. VL - 165 UR - https://doi.org/10.1016/j.cell.2016.03.029 DO - 10.1016/j.cell.2016.03.029 ID - Tape2016 ER - TY - JOUR AU - Vizcaíno, J. A. AU - Csordas, A. AU - Del-Toro, N. PY - 2016 DA - 2016// TI - 2016 update of the PRIDE database and its related tools JO - Nucleic Acids Res VL - 44 UR - https://doi.org/10.1093/nar/gkv1145 DO - 10.1093/nar/gkv1145 ID - Vizcaíno2016 ER -